新型CD19-1XX校准信号嵌合抗原受体治疗大B细胞淋巴瘤的首次人体I期研究结果
该首次人体I期剂量递增与扩展试验纳入28例复发或难治性大B细胞淋巴瘤患者,接受19(T2)28z-1XX CAR T细胞治疗,四个剂量水平为25至200×10^6。全队列总缓解率82%、完全缓解率71%,最低剂量25×10^6扩展组16例中总缓解率88%、完全缓解率75%;≥3级细胞因子释放综合征和免疫效应细胞相关神经毒性综合征发生率分别为4%和7%。
要点
- 全队列总缓解率82%、完全缓解率71%,最低剂量25×10^6扩展组总缓解率88%、完全缓解率75%。
- 中位随访24个月,1年无事件生存率61%(95%CI 45至82),14例持续完全缓解超过12个月。
- 全队列≥3级细胞因子释放综合征发生率4%、免疫效应细胞相关神经毒性综合征发生率7%。
核心结论
- 1XX CAR的校准效力在低细胞剂量下获得良好疗效和有利毒性特征,可能有益于其他血液系统恶性肿瘤、实体瘤和自身免疫病的治疗。
研究设计与样本
- 首次人体I期剂量递增和扩展临床试验,纳入复发或难治性大B细胞淋巴瘤患者,接受19(T2)28z-1XX CAR T细胞治疗,四个剂量水平范围为25至200×10^6。
- 28例患者接受白细胞分离并接受CAR T细胞,剂量递增队列16例、扩展队列12例。
主要发现
- 全队列总缓解率为82%、完全缓解率为71%。
- 最低剂量25×10^6被选为剂量扩展;该剂量水平治疗的16例患者中,88%达到总缓解、75%达到完全缓解。
- 中位随访24个月,1年无事件生存率为61%(95%CI 45至82),14例患者持续完全缓解超过12个月。
- 所有队列中,≥3级细胞因子释放综合征和免疫效应细胞相关神经毒性综合征发生率分别为4%和7%。
- 1XX CAR T细胞产品含有更高比例的具有记忆特征的CD8 T细胞,在持续缓解患者中检测到CAR T细胞持久存在超过1至2年。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We designed a CD19-targeted chimeric antigen receptor (CAR) comprising a calibrated signaling module, termed 1XX, that differs from that of conventional CD28/CD3ζ and 4-1BB/CD3ζ CARs. Preclinical data demonstrated that 1XX CARs generated potent effector function without undermining T-cell persistence. We hypothesized that 1XX CAR T cells may be effective at low doses and elicit minimal toxicities. METHODS: In this first-in-human, phase I, dose escalation and expansion clinical trial, patients with relapsed or refractory large B-cell lymphoma received 19(T2)28z-1XX CAR T cells at four dose levels (DLs), ranging from 25 to 200 × 106. RESULTS: Twenty-eight patients underwent apheresis and received CAR T cells. Sixteen and 12 patients were treated in the dose escalation and expansion cohorts, respectively. The overall response rate (ORR) was 82% and complete response (CR) rate was 71% in the entire cohort. The lowest dose of 25 × 106 was selected for dose expansion. In 16 patients treated at this DL, 88% achieved ORR and 75% CR. With the median follow-up of 24 months, the 1-year event-free survival was 61% (95% CI, 45 to 82) and 14 patients remain in continuous CR beyond 12 months. In all cohorts, grade ≥3 cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome rates were low at 4% and 7%, respectively. 1XX CAR T-cell products contain a higher proportion of CD8 T cells with memory features, and CAR T-cell persistence has been detected beyond 1-2 years in patients with ongoing remission. CONCLUSION: The calibrated potency of the 1XX CAR affords excellent efficacy at low cell doses with favorable toxicity profiles and may benefit the treatment of other hematologic malignancies, solid tumors, and autoimmunity.
引用
- Park JH, Palomba ML, Perica K, et al. Results From First-in-Human Phase I Study of a Novel CD19-1XX Chimeric Antigen Receptor With Calibrated Signaling in Large B-Cell Lymphoma. J Clin Oncol. 2025. PMID: 39883889. doi:10.1200/JCO-24-02424
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。